Male and Females >18 years at the time of screening
Patients must have proven genetic disease (confirmed by assessment of heteroplasmy in blood and urine samples) of the m.3243 A>G mutation.
Capacity to provide informed consent taken before any study related activities.
Ability and willingness to adhere to the protocol, including all appointments.
Ability to read and converse in English.

Male and Females >18 years at the time of screening
Capacity to provide informed consent taken before any study related activities.
Ability and willingness to adhere to the protocol, including all appointments.
Ability to read and converse in English.

DNA will be extracted from stool samples and the 16S rRNA gene (V4 region) will be sequenced. The DNA will then be stored in the Newcastle Mitochondrial Research Biobank

Mitochondrial Diseases

Grainne Gorman

Mitochondrial and Microbiota Relationship

Can Metagenomic and Metadata be Combined Using Bioinformatics and Computational Biology Methods to Personalise Patient Treatment.

DNA will be extracted from stool samples and the 16S rRNA gene (V4 region) will be sequenced.

Newcastle University

Newcastle-upon-Tyne Hospitals NHS Trust

Patients will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.

Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]

Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1,5% solution which will be continued for 24 hours after surgery.

Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.

Obesity

Bariatric Surgery Candidate

Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]

Placebo

Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]

Lidocaine 1%

Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]

Lidocaine 1.5%

Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]

Lidocaine 2%

Mansoura University Hospitals

Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Bariatric Surgery

Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Laparoscopic Bariatric Surgery: A Dose Dependent Study

Times to first passage of flatus, first defecation, and tolerating liquids measured in hours from the end of surgery. Patients will be asked to note the time they will be able to tolerate liquids and their first passage of flatus ("gas").

Heart rate will be recorded before induction of anesthesia, 5 min after induction, every 15 min intraoperatively, and then 1 h, 4 h, 12 h, 24 h, 36 h, 48 h after surgery

Blood pressure will be recorded before induction of anesthesia, 5 min after induction, every 15 min intraoperatively, and then 1 h, 4 h, 12 h, 24 h, 36 h, 48 h after surgery

Four-hourly pain scores at rest and during movement and cough

Fentanyl0.5 micrograms/kilogram of body weight will be administered intravenously on the discretion of the charged anesthesiologist in case of inadequate intraoperative analgesia

The volume of intravenously administered fluid therapy will be recorded before, during, and after surgery.

The volume of intravenously administered norepinephrine to treat low blood pressure will be recorded before, during, and after surgery.

The volume of intravenously administered dobutamine to treat low cardiac output will be recorded before, during, and after surgery.

The balance between the fluid intake and output during surgery and 34 hours and 48 hours after surgery will be recorded

Intravenous morphine will be administered intravenously as per request of the participants to relief their postoperative pain. The cumulative consumption of morphine by participants will be recorded at 24 hours and 48 hours after surgery

Times to spontaneous breathing, eye opening, obeying verbal commands, and extubation

It will be assessed using as assessed by a mini mental score preoperatively (baseline) and 24 h and 48 h after surgery

This will be assessed using a 100-point scale with 1 = completely dissatisfied to 100 = completely satisfied) will be recorded on postoperative day (POD)s 1, and 2

It will be scored 4-hourly as follows; (0: no nausea; 1: nausea no vomiting; 2: nausea and vomiting)

This will be assessed at four hourly as follows pruritus rated using a categorical scale (0, none; 1, mild; 2, moderate; and 3, severe)

This will be assessed at 4-hourly using sedation score (four-point verbal rating scores (VRS): awake, drowsy, arousable or deep sleep)

These include the occurrence of bleeding, fever, wound dehiscence, wound infection, anastomotic leak, abscess, peritonitis, infection

These include preoperative diabetes, renal impairment, hepatic dysfunction, cardiac dysfunction, pulmonary disease, endocrine disease

These adverse events include arrhythmia, sedation, nausea and vomiting, light-headedness, headache, perioral numbness, tunnel vision, or seizures

Mansoura University

Left Gastric Artery Embolization - Embolic Agent - BeadBlock 300 - 500 Micron will be used as the embolic agent to embolize left gastric artery.

Arterial Embolization

Other Surgical Procedures

Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.

BeadBlock 300 - 500 Micron

Left Gastric Artery Embolization

Dayton Interventional Radiology

Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically

Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically (GET LEAN)

Safety outcomes involving the use of left gastric artery embolization for the purpose of weight loss.

SF36-V2 / pre and post procedure to determine the changes of quality in life; everyday activities

Measuring changes in ghrelin, leptin, and CCK before and after left gastric embolization

intestinal pseudo-obstruction/lihavuus

Mitochondrial and Microbiota Relationship

Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Bariatric Surgery

Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically

Täydellisin lääketieteellinen tietokanta tieteen tukemana